Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Gains from Sales and Divestitures (2024 - 2025)

Metagenomi (MGX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $308058.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 38.28% to $308058.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $308058.0, a 38.28% decrease, with the full-year FY2025 number at $308058.0, down 38.28% from a year prior.
  • Gains from Sales and Divestitures was $308058.0 for Q4 2025 at Metagenomi, up from $119874.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $499148.0 in Q4 2024 to a low of $94413.0 in Q1 2025.